Community-acquired pneumonia related to intracellular pathogens.

Catia Cillóniz, Antoni Torres, Michael Niederman, Menno van der Eerden, James Chalmers, Tobias Welte, Francesco Blasi
Author Information
  1. Catia Cillóniz: Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB)-SGR 911-Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain.
  2. Antoni Torres: Department of Pneumology, Institut Clinic del Tórax, Hospital Clinic of Barcelona Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB)-SGR 911-Ciber de Enfermedades Respiratorias (Ciberes), Barcelona, Spain. atorres@clinic.ub.es.
  3. Michael Niederman: Division of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.
  4. Menno van der Eerden: Department of Pulmonary diseases, Erasmus Medical Centre, Rotterdam, The Netherlands.
  5. James Chalmers: Scottish Centre for Respiratory Research, University of Dundee, Dundee, DD1 9SY, UK.
  6. Tobias Welte: Department of Pulmonary Medicine, Hannover Medical School and Member of the German Center of Lung Research (DZL), Hannover, Germany.
  7. Francesco Blasi: Department of Pathophysiology and Transplantation, Università degli Studi di Milano, IRCCS Fondazione Ospedale Maggiore Policlinico Cà Granda, Milan, Italy.

Abstract

Community-acquired pneumonia (CAP) is associated with high rates of morbidity and mortality worldwide; the annual incidence of CAP among adults in Europe has ranged from 1.5 to 1.7 per 1000 population. Intracellular bacteria are common causes of CAP. However, there is considerable variation in the reported incidence between countries and change over time. The intracellular pathogens that are well established as causes of pneumonia are Legionella pneumophila, Mycoplasma pneumoniae, Chlamydophila pneumoniae, Chlamydophila psittaci, and Coxiella burnetii. Since it is known that antibiotic treatment for severe CAP is empiric and includes coverage of typical and atypical pathogens, microbiological diagnosis bears an important relationship to prognosis of pneumonia. Factors such as adequacy of initial antibiotic or early de-escalation of therapy are important variables associated with outcomes, especially in severe cases. Intracellular pathogens sometimes appear to cause more severe disease with respiratory failure and multisystem dysfunction associated with fatal outcomes. The clinical relevance of intracellular pathogens in severe CAP has not been specifically investigated. We review the prevalence, general characteristics, and outcomes of severe CAP cases caused by intracellular pathogens.

Keywords

References

  1. J Infect Chemother. 2010 Jun;16(3):162-9 [PMID: 20186455]
  2. Am J Med. 2014 Oct;127(10):1010.e11-9 [PMID: 24813862]
  3. Clin Infect Dis. 2005 Mar 15;40(6):800-6 [PMID: 15736011]
  4. Int J Epidemiol. 1987 Jun;16(2):282-7 [PMID: 3301708]
  5. Clin Infect Dis. 2000 Aug;31(2):347-82 [PMID: 10987697]
  6. Eur Respir J. 2003 May;21(5):779-84 [PMID: 12765420]
  7. Postgrad Med. 2010 Mar;122(2):130-41 [PMID: 20203464]
  8. Pediatr Infect Dis J. 2009 Aug;28(8):693-6 [PMID: 19633515]
  9. Emerg Infect Dis. 2014 Jun;20(6):1072-5 [PMID: 24857411]
  10. Clin Infect Dis. 2010 Jul 15;51(2):189-94 [PMID: 20540621]
  11. J Infect Chemother. 2015 Mar;21(3):153-60 [PMID: 25533771]
  12. Semin Respir Crit Care Med. 2012 Jun;33(3):244-56 [PMID: 22718210]
  13. Clin Infect Dis. 2000 Dec;31(6):1507-11 [PMID: 11096025]
  14. Eur J Clin Microbiol Infect Dis. 2012 Oct;31(10):2713-8 [PMID: 22538796]
  15. Curr Opin Infect Dis. 2010 Apr;23(2):152-7 [PMID: 20051846]
  16. J Chin Med Assoc. 2007 Aug;70(8):318-23 [PMID: 17698431]
  17. BMC Infect Dis. 2010 Mar 16;10:69 [PMID: 20230650]
  18. Clin Infect Dis. 2007 Dec 15;45(12):e147-55 [PMID: 18190309]
  19. Eur Respir J. 2012 Oct;40(4):931-8 [PMID: 22267760]
  20. Kansenshogaku Zasshi. 2015 Jul;89(4):458-64 [PMID: 26554221]
  21. J Med Microbiol. 2016 Feb;65(2):142-6 [PMID: 26704297]
  22. J Infect. 2008 Sep;57(3):223-8 [PMID: 18656264]
  23. Respirology. 2009 Nov;14(8):1098-105 [PMID: 19818051]
  24. Clin Infect Dis. 2013 Nov;57(9):1275-81 [PMID: 23899682]
  25. Euro Surveill. 2013 Dec 12;18(50):20656 [PMID: 24342515]
  26. Diagn Microbiol Infect Dis. 2003 Feb;45(2):85-95 [PMID: 12614979]
  27. Epidemiol Infect. 2014 Sep;142(9):1905-10 [PMID: 24252152]
  28. Pathog Dis. 2015 Feb;73(1):1-15 [PMID: 25853998]
  29. BMC Infect Dis. 2010 Feb 25;10:39 [PMID: 20184731]
  30. Chest. 2009 Dec;136(6):1576-1585 [PMID: 19318671]
  31. Methods Mol Biol. 2013;954:27-56 [PMID: 23150388]
  32. Clin Microbiol Rev. 2004 Oct;17(4):697-728, table of contents [PMID: 15489344]
  33. BMC Infect Dis. 2013 Apr 11;13:172 [PMID: 23578215]
  34. Medicine (Baltimore). 2008 May;87(3):152-9 [PMID: 18520324]
  35. Chest. 2013 Sep;144(3):990-998 [PMID: 23744173]
  36. Arch Intern Med. 1997 Aug 11-25;157(15):1709-18 [PMID: 9250232]
  37. Epidemiol Infect. 2013 Jan;141(1):62-73 [PMID: 22475210]
  38. Clin Infect Dis. 2007 Mar 1;44 Suppl 2:S27-72 [PMID: 17278083]
  39. Int J Antimicrob Agents. 2003 Jun;21(6):574-7 [PMID: 12791472]
  40. BMC Infect Dis. 2012 Jun 12;12:134 [PMID: 22691449]
  41. Emerg Infect Dis. 2011 Apr;17(4):668-75 [PMID: 21470457]
  42. Public Health. 2006 Jun;120(6):566-71 [PMID: 16707144]
  43. J Infect Chemother. 2014 Mar;20(3):181-5 [PMID: 24462437]
  44. Intensive Care Med. 2011 Feb;37(2):214-23 [PMID: 21080155]
  45. J Negat Results Biomed. 2016 Mar 02;15:3 [PMID: 26932735]
  46. Can Vet J. 1990 Aug;31(8):555-63 [PMID: 17423643]
  47. Clin Infect Dis. 2014 Feb;58(3):330-9 [PMID: 24270053]
  48. Diagn Microbiol Infect Dis. 2011 May;70(1):1-9 [PMID: 21397428]
  49. Ned Tijdschr Geneeskd. 2006 Jan 21;150(3):117-21 [PMID: 16463610]
  50. J Antimicrob Chemother. 2013 Mar;68(3):506-11 [PMID: 23169891]
  51. Int J Antimicrob Agents. 1997;8(3):145-61 [PMID: 18611796]
  52. J Chemother. 2010 Aug;22(4):264-6 [PMID: 20685631]
  53. J Med Microbiol. 2007 Dec;56(Pt 12):1625-9 [PMID: 18033831]
  54. Am J Trop Med Hyg. 1989 Feb;40(2):197-9 [PMID: 2645804]
  55. Clin Microbiol Infect. 2009 Jan;15(1):36-41 [PMID: 19220338]
  56. Euro Surveill. 2015;20(48):30078 [PMID: 26675545]
  57. Thorax. 2009 Oct;64 Suppl 3:iii1-55 [PMID: 19783532]
  58. N Engl J Med. 2015 Jul 30;373(5):415-27 [PMID: 26172429]
  59. Emerg Infect Dis. 2011 Apr;17(4):579-83 [PMID: 21470444]
  60. Commun Dis Rep CDR Rev. 1996 Aug 16;6(9):R128-32 [PMID: 8810119]
  61. Emerg Infect Dis. 2014 Nov;20(11):1795-1802 [PMID: 25513657]
  62. Chest. 2007 Apr;131(4):1205-15 [PMID: 17426229]
  63. Eur Respir J. 2003 May;21(5):741-2 [PMID: 12765413]
  64. J Infect Dis. 2002 Jul 1;186(1):127-8 [PMID: 12089674]
  65. Am J Trop Med Hyg. 2015 Feb;92(2):244-6 [PMID: 25404074]
  66. Chest. 2002 May;121(5):1493-7 [PMID: 12006434]
  67. Curr Opin Infect Dis. 2004 Apr;17(2):137-42 [PMID: 15021054]
  68. Scand J Infect Dis. 2014 Jul;46(7):486-92 [PMID: 24856893]
  69. Emerg Infect Dis. 2015 Mar;21(3):426-34 [PMID: 25693633]
  70. Infect Immun. 2005 May;73(5):2828-34 [PMID: 15845487]
  71. Proc Natl Acad Sci U S A. 1981 May;78(5):3240-4 [PMID: 6942430]
  72. FEMS Immunol Med Microbiol. 2012 Feb;64(1):3-12 [PMID: 22066649]
  73. FEMS Microbiol Rev. 2008 Nov;32(6):956-73 [PMID: 18754792]
  74. Am J Respir Crit Care Med. 2007 May 15;175(10):1086-93 [PMID: 17332485]
  75. Antimicrob Agents Chemother. 2000 Jul;44(7):1980-2 [PMID: 10858366]
  76. Crit Care. 2011;15(5):R209 [PMID: 21914220]
  77. Clin Microbiol Infect. 2009 Jan;15(1):29-35 [PMID: 19220337]
  78. J Infect Chemother. 2011 Feb;17 (1):114-8 [PMID: 20676912]
  79. Mayo Clin Proc. 2008 May;83(5):574-9 [PMID: 18452690]
  80. Medicine (Baltimore). 2013 Jan;92(1):51-60 [PMID: 23266795]
  81. Clin Microbiol Infect. 2007 Jul;13(7):743-6 [PMID: 17403130]
  82. N Engl J Med. 2016 Feb 4;374(5):497-8 [PMID: 26840151]
  83. J Manag Care Pharm. 2009 Mar;15(2 Suppl):S5-11 [PMID: 19236135]
  84. APMIS. 2005 Feb;113(2):99-111 [PMID: 15723684]
  85. Curr Opin Pulm Med. 2014 May;20(3):247-51 [PMID: 24626238]
  86. PLoS One. 2014 Mar 10;9(3):e91764 [PMID: 24614585]
  87. Chest. 2013 Sep;144(3):999-1007 [PMID: 23670047]
  88. Thorax. 2012 Jan;67(1):71-9 [PMID: 20729232]
  89. J Clin Microbiol. 2000 May;38(5):1709-12 [PMID: 10790085]
  90. J Med Microbiol. 2008 Oct;57(Pt 10):1296-8 [PMID: 18809562]
  91. APMIS. 2004 Nov-Dec;112(11-12):785-807 [PMID: 15638838]
  92. Curr Med Res Opin. 2004 Apr;20(4):555-63 [PMID: 15119993]
  93. Eur Respir J Suppl. 2002 Jul;36:20s-27s [PMID: 12168744]
  94. Eur Respir J. 2004 Jul;24(1):171-81 [PMID: 15293621]
  95. Thorax. 2011 Apr;66(4):340-6 [PMID: 21257985]
  96. Am J Respir Crit Care Med. 2001 Jun;163(7):1730-54 [PMID: 11401897]
  97. Intern Med. 2014;53(15):1675-8 [PMID: 25088885]
  98. Thorax. 1992 Apr;47(4):276-8 [PMID: 1585291]
  99. MMWR Recomm Rep. 2013 Mar 29;62(RR-03):1-30 [PMID: 23535757]
  100. Dtsch Med Wochenschr. 2011 Apr;136(15):775-80 [PMID: 21469047]
  101. Acta Microbiol Immunol Hung. 2012 Jun;59(2):171-84 [PMID: 22750778]

MeSH Term

Anti-Bacterial Agents
Chlamydophila pneumoniae
Community-Acquired Infections
Coxiella burnetii
Europe
Gram-Negative Bacterial Infections
Humans
Legionella pneumophila
Mycoplasma pneumoniae
Pneumonia, Bacterial

Chemicals

Anti-Bacterial Agents

Word Cloud

Created with Highcharts 10.0.0pathogensCAPpneumoniasevereintracellularCommunity-acquiredassociatedIntracellularoutcomesincidence1causespneumoniaeChlamydophilaantibioticimportantcaseshighratesmorbiditymortalityworldwideannualamongadultsEuroperanged57per1000populationbacteriacommonHoweverconsiderablevariationreportedcountrieschangetimewellestablishedLegionellapneumophilaMycoplasmapsittaciCoxiellaburnetiiSinceknowntreatmentempiricincludescoveragetypicalatypicalmicrobiologicaldiagnosisbearsrelationshipprognosisFactorsadequacyinitialearlyde-escalationtherapyvariablesespeciallysometimesappearcausediseaserespiratoryfailuremultisystemdysfunctionfatalclinicalrelevancespecificallyinvestigatedreviewprevalencegeneralcharacteristicscausedrelatedEtiologyPneumonia

Similar Articles

Cited By (50)